Apex’s partner for driving simulation studies, Cognitive Research Corporation, authored an article (https://doi.org/10.1111/cts.13145) about a clinical trial assessing the effect of Rapastinel on driving performance (NCT03814733). The trial, in which 107 healthy participants were enrolled, was conducted at two study centers including the Long Beach, CA location of Collaborative Neuroscience Research (CNS). The results of…
Read MorePosts by Clinical Trial Centers
Apex Principal Investigators, Drs. Howard Hassman and David Walling at Hassman Research Institute (HRI) and Collaborative Neuroscience Research (CNS), respectively, authored in collaboration with Rovi an article about a crucial clinical trial (NCT03527186) assessing the steady-state comparative bioavailability of risperidone in situ microimplants (ISM) and oral risperidone in 104 patients with schizophrenia. The study…
Read MoreBringing almost 30 years of experience in the pharmaceutical and clinical trials industry, Tom Zoda, Ph.D. has joined Apex Innovative Sciences as Chief Operating Officer. In his role as COO, Dr. Zoda will work with the executive team to develop and implement strategies to grow Apex as a market leader in the Phase I-III clinical…
Read MoreApex Innovative Sciences Appoints Brett A. English, Pharm.D., Ph.D., as Vice President of Scientific Affairs MARLTON, N.J. and GARDEN GROVE, Calif., April 8, 2021 — Apex Innovative Sciences (“Apex”), an industry-leading independent provider of clinical drug development and trial site services, today announced the appointment of Brett A. English, Pharm.D., Ph.D., as Vice President of…
Read MoreBioXcel Therapeutics, a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, will host a virtual Key Opinion Leader (“KOL”) event on Friday, February 19, 2021 from 11:00 am to 2:00 pm ET. The event aims to highlight BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of…
Read MoreLarry Ereshefsky, Pharm.D., Chief Scientific Officer of Apex Innovative Sciences, has published more than 130 peer-reviewed scholarly articles and abstracts. His latest work, “Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant,” has been published in the medical journal, Expert Review of Pharmacoeconomics & Outcomes…
Read MoreOur annual eCards are here and updated for 2021. Download the neuroscience-focused card as well as the general medical version. We’re excited to connect with you during these conferences. Virtual and Zoom meetings will keep us safer for now, and we’re hopeful that we’ll return to in-person conversations in the near future. Please check each…
Read MoreMARLTON, N.J. and GARDEN GROVE, Calif., Jan. 5, 2021 — Apex Innovative Sciences (Apex) and its affiliates are proud to announce their participation in three COVID-19 vaccine studies. With East and West Coast operations and six state-of-the-art clinical trial facilities, Apex is strongly positioned to pivot from its core central nervous system (CNS) business and…
Read MoreHoward Hassman, D.O., AOBFP discussed the formation of Apex Innovative Sciences, the COVID-19 vaccine studies conducted by Hassman Research Institute and CNS Research, and the use of psychedelics to treat a variety of disorders with Kevin Price, Host of The Price of Business Show. Listen to the interview in its entirety.
Read MoreNeurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced positive top-line results from the Phase 1 central nervous effects (CNS) clinical study of tolperisone. The study, utilizing a validated driving test, confirmed that tolperisone does not impair driving performance. In addition, tolperisone does not appear to cause sleepiness, a side…
Read More